Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)
Crossref DOI link: https://doi.org/10.1007/s10549-016-3822-z
Published Online: 2016-06-08
Published Print: 2016-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Matter-Walstra, K.
Ruhstaller, T.
Klingbiel, D.
Schwenkglenks, M.
Dedes, K. J.
License valid from 2016-06-08